HIGHLIGHTS
- who: u0426u0435u0440u0435u0431u0440u043eu0432u0430u0441u043au0443u043bu044fu0440u043du044bu0435 u0437u0430u0431u043eu043bu0435u0432u0430u043du0438u044f et al. from the Vagner Perm State Medical UniversityVagner Perm State Medical University have published the research: u041eu0440u0438u0433u0438u043du0430u043bu044cu043du0430u044f u0441u0442u0430u0442u044cu044f / Original Article u0438u043du0441u0443u043bu044cu0442u0435:, in the Journal: (JOURNAL)
SUMMARY
Intravenous thrombolysis (IT) is the primary method of reperfusion therapy for ischemic stroke. To evaluate the efficacy and safety of the use of non-immunogenic staphylokinase for IT in ischemic stroke in real-world clinical practice of the regional vascular center. Syromyatnikova L.I., Krapivin S. Experience with non-immunogenic staphylokinase for intravenous thrombolysis in ischemic stroke: analysis of hospital registry data. Выделение патогенетических вариантов инсульта проводилось на основании классификации SSSTOAST . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.